Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational studyPLoS Medicine.  16. 2019
2019 Stereotactic radiosurgery with MLC-defined arcs: Verification of dosimetry, spatial accuracy, and end-to-end testsJournal of Applied Clinical Medical Physics.  20:84-98. 2019
2019 Pathologic Predictors of Local Recurrence in Atypical Meningiomas Following Gross Total ResectionInternational Journal of Radiation Oncology - Biology - Physics.  103:453-459. 2019
2019 Differential escape mechanisms in cetuximab-resistant head and neck cancer cellsBiochemical and Biophysical Research Communications2019
2018 The virtual cone: A novel technique to generate spherical dose distributions using a multileaf collimator and standardized control-point sequence for small target radiation surgeryAdvances in Radiation Oncology.  3:421-430. 2018
2018 MicroRNA-31 is required for astrocyte specificationGlia.  66:987-998. 2018
2018 A method for pre-operative single-subject thalamic segmentation based on probabilistic tractography for essential tremor deep brain stimulationNeuroradiology.  60:303-309. 2018
2018 Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal diseaseJournal of Clinical Neuroscience.  49:48-55. 2018
2018 Structural connectivity–based segmentation of the thalamus and prediction of tremor improvement following thalamic deep brain stimulation of the ventral intermediate nucleusNeuroImage: Clinical.  20:1266-1273. 2018
2017 Macropinocytosis of bevacizumab by glioblastoma cells in the perivascular niche affects their survivalClinical Cancer Research.  23:7059-7071. 2017
2017 Fractionated stereotactic radiation therapy for intact brain metastasesAdvances in Radiation Oncology.  2:564-571. 2017
2017 Epigenetic regulation of ZBTB18 promotes glioblastoma progressionCell Growth and Differentiation.  15:998-1011. 2017
2017 KLF6 depletion promotes NF-κB signaling in glioblastomaOncogene.  36:3562-3575. 2017
2017 Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525JAMA Oncology.  3:784-792. 2017
2017 Distant brain recurrence in patients with five or more newly diagnosed brain metastases treated with focal stereotactic radiotherapy alone.Journal of Radiosurgery and SBRT.  4:255-263. 2017
2016 Coneless Linear Accelerator-Based Volumetric Modulated Arc Therapy Stereotactic Radiosurgery Technique for Functional Disorders.International Journal of Radiation Oncology - Biology - Physics.  96:E657-E658. 2016
2016 Distant Brain Recurrence in Patients With 5 or More Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiation Therapy (FSRT) Alone.International Journal of Radiation Oncology - Biology - Physics.  96:E67. 2016
2016 Stereotactic Hypofractionated Radiation Therapy for Intact Brain Metastases.International Journal of Radiation Oncology - Biology - Physics.  96:E120-E121. 2016
2016 A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomasJournal of Neuro-Oncology.  129:139-146. 2016
2016 SU-F-J-96: Comparison of Frame-Based and Mutual Information Registration Techniques for CT and MR Image Sets.Medical Physics.  43:3428-3429. 2016
2015 Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 InhibitionBMC Cancer.  15. 2015
2015 Neuronal activity promotes glioma growth through neuroligin-3 secretionCell.  161:803-816. 2015
2015 Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapyNeuro-Oncology.  17:392-406. 2015
2015 Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastomaOncotarget.  6:17805-17816. 2015
2014 Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: The University of Alabama at Birmingham experienceNeuro Oncology Practice.  1:172-177. 2014
2014 Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progressionJournal of Clinical Investigation.  124:2861-2876. 2014
2014 A20 expressing tumors and anticancer drug resistanceAdvances in Experimental Medicine and Biology.  809:65-81. 2014
2014 Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variationRadiology.  270:212-222. 2014
2014 Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolinesRadiotherapy and Oncology.  111:468-474. 2014
2013 Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastomaClinical Cancer Research.  19:6484-6494. 2013
2013 Feature selection and survival modeling in The Cancer Genome AtlasInternational Journal of Nanomedicine.  8:57-62. 2013
2013 RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patientsInternational Journal of Radiation Oncology - Biology - Physics.  85:1206-1211. 2013
2012 Laminin alpha 2 enables glioblastoma stem cell growthAnnals of Neurology.  72:766-778. 2012
2012 Glioblastoma multiformeNeurology Research International.  2012. 2012
2012 Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastomaJournal of Cellular and Molecular Medicine.  16:545-554. 2012
2011 Gene-protein correlation in single cellsNeuro-Oncology.  13:880-885. 2011
2011 The authors replyNew England Journal of Medicine.  365:277-278. 2011
2011 Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2Cell.  146:53-66. 2011
2011 Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3Cancer Cell.  19:498-511. 2011
2011 NFKBIA deletion in glioblastomasNew England Journal of Medicine.  364:627-637. 2011
2010 A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomasCancer.  116:5297-5305. 2010
2009 Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adultsBMC Cancer.  9:372. 2009
2009 Translating biological insights into clinical endpoints in neuro-oncologyLancet Oncology.  10:928-929. 2009
2009 A network model of a cooperative genetic landscape in brain tumorsJournal of the American Medical Association.  302:261-275. 2009
2009 Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomasJournal of the American Medical Association.  302:276-289. 2009
2009 Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme.Journal of Clinical Oncology.  27:2028. 2009
2009 Genomics of human intracranial aneurysm wallStroke.  40:1252-1261. 2009
2008 Use of gene signatures to improve risk estimation in cancerJournal of the American Medical Association.  299:1605-1606. 2008
2008 Nomograms as clinicobiological predictors of survival in glioblastomaLancet Oncology.  9:5-6. 2008
2007 Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumorsMethods in Molecular Biology.  377:187-202. 2007
2007 CHD5 Is a Tumor Suppressor at Human 1p36Cell.  128:459-475. 2007
2007 Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.Methods in Molecular Biology.  377:187-202. 2007
2006 Tumor necrosis factor-α-induced protein 3 down-regulates nuclear factor-κB-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas.Journal of Clinical Oncology.  24:1508. 2006
2006 Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomasJournal of Clinical Oncology.  24:274-287. 2006
2005 Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomasCancer Research.  65:8679-8689. 2005
2005 893 High-resolution Mapping of Human Glioma Genomes.Neurosurgery.  57:427-428. 2005
2005 High-resolution genome-wide mapping of genetic alterations in human glial brain tumorsCancer Research.  65:4088-4096. 2005
2005 Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNAJournal of Molecular Diagnostics.  7:171-182. 2005
2005 DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomas.International Journal of Oncology.  26:1187-1192. 2005
2004 Chemogenomics: An emerging strategy for rapid target and drug discoveryNature Reviews Genetics.  5:262-275. 2004
2004 Genomics-based hypothesis generation: A novel approach to unravelling drug resistance in brain tumours?Lancet Oncology.  5:89-100. 2004
2003 Predicting outcome and tailoring treatment in high-grade gliomasLancet Oncology.  4:269-270. 2003
2003 Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypesBrain Pathology.  13:133-143. 2003
2002 Expression of DNA topoisomerase IIα in oligodendrogliomaAnticancer Research.  22:1301-1304. 2002
2002 High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival in glioblastoma patientsEuropean journal of cancer.  38:1343-1347. 2002
2002 DNA topoisomerase IIα predicts progression-free and overall survival in pediatric malignant non-brainstem gliomasInternational Journal of Cancer.  99:817-820. 2002
2002 Expression of DNA topoisomerase IIalpha in oligodendroglioma.Anticancer Research.  22:1301-1304. 2002
2002 DNA topoisomerase IIα expression in optic pathway gliomas of childhoodEuropean journal of cancer.  38:393-400. 2002
2002 Brain-tumour drug resistance: The bare essentialsLancet Oncology.  3:397-406. 2002
2001 Anticancer drug resistance in primary human brain tumorsBrain Research Reviews.  35:161-204. 2001
1999 Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II - Preclinical studies in a nude mouse modelNeurosurgery.  45:1208-1215. 1999
1999 Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhoodClinical Cancer Research.  5:1786-1792. 1999
1999 Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashionJournal of Neuro-Oncology.  41:9-20. 1999
1999 The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomasBrain Research Reviews.  29:232-249. 1999
1998 Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumorsPediatric Neurosurgery.  29:228-244. 1998
1998 Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growthNeurosurgery.  43:124-132. 1998
1997 Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomasClinical Cancer Research.  3:2157-2164. 1997
1997 The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapyActa Neurochirurgica.  139:1000-1013. 1997

Chapter

Year Title Altmetric
2014 Primary Tumors of the Nervous System 2014
2013 Primary Tumors of the Nervous System.  1-22. 2013

Education And Training

  • Doctor of Medicine, University of Vienna 2001
  • Doctor of Philosophy in Medical Neurobiology, Free University of Berlin 2001
  • UAB Hospital, Residency 2014
  • Stanford University School of Medicine, Postdoctoral Fellowship 2005
  • Full Name

  • Markus Bredel